In the past decade, the emergence of chimeric antigen receptor (CAR) T-cell therapy has led
to a cellular immunotherapy revolution against various cancers. Although CAR-T cell …

Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …

Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer
immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical …

Abstract H3K27M-mutant diffuse midline gliomas (DMGs) express high levels of the
disialoganglioside GD2 (ref.). Chimeric antigen receptor-modified T cells targeting GD2 …

CD19-directed chimeric antigen receptor (CD19CAR) T-cell therapy has been successful in
treating several B-cell lineage malignancies, including B-cell non-Hodgkin lymphoma …

Chimeric antigen receptor (CAR) T cell therapeutic responses are hampered by limited T
cell trafficking, persistence, and durable anti-tumor activity in solid tumors. However, these …

Simple Summary Clinical trials in glioblastoma (GBM) using CAR-T cells have not yielded
tangible results. However, clinical and immunological observations from the trials have …

Chimeric antigen receptor (CAR) T cells targeting CD19 mediate potent antitumor effects in
B-cell malignancies including acute lymphoblastic leukemia (ALL), but antigen loss remains …

Intrathecal delivery (IT) of opiates into the cerebrospinal fluid (CSF) for anesthesia and pain
relief has been used clinically for decades, but this relatively straightforward approach of …

Simple Summary Primary or secondary central nervous system (CNS) lymphoma is
frequently associated with a poor prognosis. CAR T-cells are being established as a …